Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02176655
Recruitment Status : Completed
First Posted : June 27, 2014
Results First Posted : March 23, 2017
Last Update Posted : March 23, 2017
Sponsor:
Collaborator:
Vivid Pharma Inc.
Information provided by (Responsible Party):
Roger K Cady, MD, Cady, Roger, M.D.

Tracking Information
First Submitted Date  ICMJE June 24, 2014
First Posted Date  ICMJE June 27, 2014
Results First Submitted Date  ICMJE August 18, 2016
Results First Posted Date  ICMJE March 23, 2017
Last Update Posted Date March 23, 2017
Study Start Date  ICMJE July 2014
Actual Primary Completion Date January 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 17, 2017)
Headache Severity 2 Hours Post Treatment [ Time Frame: Immediately Prior to Treatment through 2 Hours Post Treatment ]
Headache severity 2 hours post treatment in sumatriptan succinate 12.5 mg and acetylsalicylic acid 325 mg (VVD-101) vs. placebo. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
Original Primary Outcome Measures  ICMJE
 (submitted: June 25, 2014)
Headache Severity 2 Hours Post Treatment [ Time Frame: Time of Treatment to 2 Hours Post Treatment ]
Headache severity 2 hours post treatment in sumatriptan succinate 12.5 mg and acetylsalicylic acid 325 mg (VVD-101) vs. placebo.
Change History Complete list of historical versions of study NCT02176655 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 17, 2017)
  • Headache Severity at Treatment, 30 Minutes and 1 Hour Post Treatment [ Time Frame: Immediately Prior to Treatment through 1 Hours Post Treatment ]
    Change in headache severity from before treatment, at 30 minutes, and 1 hour post treatment in attacks treated with VVD-101 vs. placebo. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Number of Headaches Relieved [ Time Frame: Immediately Prior to Treatment to 2 Hours Post Treatment ]
    Headache relief from before treatment, at 30 minutes, 1 hour, and 2 hours post treatment in attacks treated with VVD-101 vs. placebo. Headache relief is defined as a headache going from moderate or severe to mild or no headache or mild headache going to no headache. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Number of Headaches Relieved to Complete Pain Freedom at Two Hours Post Treatment [ Time Frame: Immediately Prior to Treatment to 2 Hours Post Treatment ]
    Number of headaches relieved (no head pain) at 2 hours post treatment for VVD-101 vs. placebo. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Number of Headaches With Sustained Pain Freedom at Twenty Four Hours Post Treatment [ Time Frame: Time of Treatment to 24 Hours Post Treatment ]
    Number of headaches with sustained headache pain freedom at 24 hours post treatment for VVD-101 vs. placebo. Sustained headache pain freedom is defined as no pain 2 hours post treatment and headache freedom continuing for 24 hours post treatment without rescue. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Number of Participants With Consistent Response to VVD-101 [ Time Frame: Response to Treatment of Three Headaches (estimated 6 months) ]
    To assess the consistency of response to VVD-101 over the three active treatments of VVD-101. Consistency is defined as meeting the requirements of headache relief 2 hours post treatment for 2 out of 3 active treated headaches. Headache relief is defined as a headache going from moderate or severe to mild or no headache or mild headache going to no headache. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Satisfaction [ Time Frame: 24 Hours Post Treatment for 3 Headaches (estimated 6 months) ]
    To assess subject satisfaction with treatment results comparing VVD-101 vs. placebo. Satisfaction was measured on a 7 point Likert scale whereas 0 = extremely dissatisfied and 6 = extremely satisfied.
  • Acute Hangover Scale Compared to Pain Severity 2 Hours Post Treatment [ Time Frame: Immediately Before Treatment of 3 Headaches to 2 Hours Post Treatment ]
    Comparison of Acute Hangover Scale (AHS) score before treatment with headache pain severity 2 hours post treatment for headaches treated with VVD-101. The AHS scale is rated on a score of 0-63. A score of 0 indicates no symptoms and a total score of 63 indicates the maximum number of reported symptoms. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 25, 2014)
  • Headache Severity at Treatment, 30 Minutes and 1 Hour Post Treatment [ Time Frame: Time of Treatment to 1 Hour Post Treatment ]
    Change in headache severity from before treatment, at 30 minutes, and 1 hour post treatment in attacks treated with VVD-101 vs. placebo.
  • Headache Relief [ Time Frame: Time of Treatment to 2 Hours Post Treatment ]
    Headache relief from before treatment, at 30 minutes, 1 hour, and 2 hours post treatment in attacks treated with VVD-101 vs. placebo. Headache relief is defined as a headache going from moderate or severe to mild or no headache or mild headache going to no headache.
  • Headache Freedom [ Time Frame: Time of Treatment to 2 Hours Post Treatment ]
    Headache freedom (no head pain) at 2 hours post treatment for VVD-101 vs. placebo.
  • Sustained Headache Freedom [ Time Frame: Time of Treatment to 24 Hours Post Treatment ]
    Sustained headache freedom 24 hours post treatment in attacks treated with VVD-101 vs. placebo. Sustained headache freedom is defined as no pain 2 hours post treatment and headache freedom continuing for 24 hours post treatment without rescue.
  • Adverse Events [ Time Frame: Post Screening to Final Study Visit (estimated 6 months) ]
    To compare adverse events of VVD-101 vs. placebo.
  • Consistency of Response [ Time Frame: Response to Treatment of Three Headaches (estimated 6 months) ]
    To assess the consistency of response to VVD-101 over the three active treatments. Consistency is defined as meeting the requirements of headache relief 2 hours post treatment for 2 out of 3 active treated headaches.
  • Satisfaction [ Time Frame: 24 Hours Post Treatment for 3 Headaches (estimated 6 months) ]
    To assess subject satisfaction with treatment results comparing VVD-101 vs. placebo.
  • Acute Hangover Scale [ Time Frame: Immediatly Before Treatment of 3 Headaches to 2 Hours Post Treatment ]
    Comparison of Acute Hangover Scale (AHS) score before treatment with headache pain severity 2 hours post treatment for headaches treated with VVD-101.
Current Other Pre-specified Outcome Measures
 (submitted: March 17, 2017)
  • Number of Drinks Consumed Compared to Pain Severity 2 Hours Post Treatment [ Time Frame: Time of Last Sitting to 2 Hours Post Treatment (estimated 14 hours) ]
    Comparison of the number of drinks consumed at one sitting with pain severity 2 hours post treatment for headaches treated with VVD-101. Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Comparing Acute Hangover Scale Individual Symptoms With Headache Severity 2 Hours Post Treatment [ Time Frame: Immediately Before Treatment to 2 Hours Post Treatment ]
    Comparison of headache severity 2 hours post treatment of headache treated with VVD-101 with each associated hangover symptom items on the AHS taken before treatment. Individual Hangover Symptoms Scores range from 0 [None] to 7 [Incapacitating]. The AHS scale is rated on a score of 0-63. A score of 0 indicates no symptoms and a total score of 63 indicates the maximum number of reported symptoms.Headache severity was measured on a 4 point Likert scale with 0 = no pain, 1 = mild pain, 2 = moderate, 3 = severe pain.
  • Meaningful Headache Relief [ Time Frame: Time of Onset to Meaningful Headache Relief (up to 24 hours) ]
    Time to meaningful headache relief for VVD-101 vs. placebo. Meaningful headache relief is defined as experiencing substantial relief as reported by the subject.
Original Other Pre-specified Outcome Measures
 (submitted: June 25, 2014)
  • Correlation of Number of Drinks Consumed with Pain Severity [ Time Frame: Time of Last Sitting to 2 Hours Post Treatment (estimated 14 hours) ]
    Correlation of the number of drinks consumed at one sitting with pain severity 2 hours post treatment for headaches treated with VVD-101.
  • Comparing Acute Hangover Scale Individual Symptoms With Headache Severity 2 Hours Post Treatment [ Time Frame: Immediately Before Treatment to 2 Hours Post Treatment ]
    Comparison of headache severity 2 hours post treatment of headache treated with VVD-101 with each associated hangover symptom items on the AHS taken before treatment.
  • Meaningful Headache Relief [ Time Frame: Time of Onset to Meaningful Headache Relief (up to 24 hours) ]
    Time to meaningful headache relief for VVD-101 vs. placebo. Meaningful headache relief is defined as experiencing substantial relief.
 
Descriptive Information
Brief Title  ICMJE Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Official Title  ICMJE Multi-Center, Double-Blind, Placebo Controlled Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Brief Summary This study proposes to compare the efficacy of sumatriptan and aspirin to placebo as an acute abortive treatment for delayed alcohol induced headache in adult subjects.
Detailed Description

The exploratory study will be conducted at 2 investigational sites. Approximately 26 subjects, 21 years of age and older, with a history of delayed alcohol induced headache, as defined by International Classification of Headache Disorders (ICHD-3 beta) will be enrolled. The study will consist of two visits. Subject participation will last approximately 6 months.

At the screening visit (Visit 1), and before any study procedures, an informed consent will be obtained from the subject. A physical, neurological exam, medication history, and pregnancy test (if appropriate) will be performed. Vital signs will be recorded for all subjects. Subjects will also complete the Simple Screening Instrument for Alcohol and Other Drugs (SSI-AOD).

Subjects scoring greater than 4 (not including items 1 and 15) on the SSI-AOD, at Visit 1, will not be eligible for this study and will be referred to their primary care provider for follow up.

Subjects meeting eligibility criteria will be randomized into 1 of 6 different groups. Each group will receive 3 doses of active drug and 3 doses of placebo in a different order to treat up to 6 delayed alcohol-induced headaches. Study product instructions will be reviewed. A copy of the instructions will be given to the subject. Subjects will be instructed they may take their investigator approved routine rescue medications for headaches 2 hours after taking the study medication if needed. Rescue medication usage and dosage will be recorded on the headache diary. Subjects may take acute headache medications as prescribed; however, this should be recorded on the headache diary. Therapy considered necessary for the subject's welfare may be given at the discretion of the investigator. Routine medications should be maintained on a stable dose and regimen for the duration of the study period.

Subjects will be instructed regarding completion of the online Headache Diary to document treatment response of up to 6 delayed alcohol-induced headaches. Subjects will be provided instructions for completing the Headache Diary. The Headache Diary will be completed during each headache and will document the number of drinks consumed in the last sitting, time of last drink consumed, pain severity, headache symptoms, and hangover symptoms before treatment, time of treatment with study products, pain severity at 30 minutes, 1, 2, and 24 hours following treatment, time of headache resolution, and time of meaningful headache relief. The Headache Diary will also include questions to evaluate subject satisfaction with study product. Subjects must be headache-free for 24 hours before recording the onset of and treating another headache. Subjects will be phoned monthly during the study to assess compliance, continued understanding, and to collect any adverse events.

Visit 2 will occur within 1 week following treatment of a 6th attack or between 180-187 days following Visit 1, whichever occurs first. The medical and medication history will be updated and adverse events will be collected. A urine pregnancy test will be performed if appropriate and vital signs to include weight and height will be performed. Subjects will complete the SSI-AOD. Subjects scoring greater than 4 (not including items 1 and 15) on the SSI-AOD will be referred to their primary care provider for follow up. The Diary will be reviewed and any unused study product and used packaging will be collected. Drug accountability will be performed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Delayed Alcohol Induced Headache
Intervention  ICMJE
  • Drug: VVD-101
    All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
    Other Name: sumatriptan succinate 12.5 mg & acetylsalicylic acid 325 mg
  • Drug: Placebo
    All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study Arms  ICMJE
  • Active Comparator: VVD-101
    One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
    Intervention: Drug: VVD-101
  • Placebo Comparator: Placebo
    One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 5, 2016)
31
Original Estimated Enrollment  ICMJE
 (submitted: June 25, 2014)
26
Actual Study Completion Date  ICMJE January 2016
Actual Primary Completion Date January 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • male or female 21 years or older.
  • able to read, understand, and sign the informed consent.
  • currently consume alcohol averaging at least four times per month.
  • a negative urine pregnancy test at Visit 1, if female, and of childbearing potential. Note: If of childbearing potential, subject must agree to maintain true abstinence or use (or have their partner use) one of the listed methods of birth control for the duration of the study: hormonal contraceptive, intrauterine device (IUD), condoms, diaphragm, and/or vasectomy. The use of barrier contraceptive (condom or diaphragm) should always be supplemented with the use of a spermicide. Note: To be considered not of childbearing potential, subject must be 6 weeks post-surgical bilateral oophorectomy, hysterectomy, or bilateral tubal ligation, or postmenopausal for at least one year.
  • at least a one year history of delayed alcohol-induced headache after light to moderate alcohol consumption.
  • able to differentiate delayed alcohol-induced headache from any other headache they may experience (e.g., tension-type headache).
  • able to stay awake for at least 2 hours after treatment following first dose of study product.
  • willing to complete the online headache diary and questionnaires.
  • concomitant medication dosages approved by the investigator.
  • internet access and an email address for completion of online diary and questionnaires.

Exclusion Criteria:

  • > 6 migraine attacks per month during the 3 months previous to screening.
  • history of receiving partial or complete relief of hangover headaches from 650 mg of aspirin.
  • history of basilar, ophthalmoplegic, or hemiplegic migraine, cluster headache, or secondary headaches (such as due to trauma, infection, alterations of homeostasis, eye, nose, throat (ENT) disorders, or psychiatric disorders, cranial or cervical disorders or neuralgias) within the previous year.
  • significant alcohol or drug use problems (score > 4 on the Simple Screening Instrument for Alcohol and Other Drugs (SSI-AOD)) or history of treatment or counseling for alcohol or drug abuse and or dependence.
  • used acute headache medication including non-prescription medications, 15 or more days per month during the last 3 months.
  • pregnant, actively trying to become pregnant, or breastfeeding.
  • female of childbearing potential not using adequate contraceptive measures.
  • has a history of serotonin syndrome or in the opinion of the investigator is at an increased risk for developing serotonin syndrome with the use of triptans.
  • in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease (based on history or the presence of risk factors including but not limited to hypertension, hypercholesterolemia, smoker, obesity, diabetes, or family history of coronary artery disease).
  • if female, has migraine with aura, is a smoker, and currently taking estrogen containing birth control pill, and in the investigator's opinion, is at high risk for cerebrovascular disease.
  • uncontrolled hypertension (≥140/90 mmHg in either systolic or diastolic in 2 out of 3 blood pressure measurements at screening).
  • history of any clinically significant medical or psychiatric condition, or evidence of substance abuse including binge drinking within the last year that, in the opinion of the investigator, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this study.
  • has hypersensitivity, intolerance, or contraindication to the use of any triptan or aspirin (including all sumatriptan and aspirin preparations).
  • has history of nasal polyps and/or asthma and in the investigator's opinion is at risk for hypersensitivity to aspirin.
  • participated in an investigational drug trial within the past 30 days.
  • planning or requiring surgery during the study.
  • history of poor compliance with medical treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02176655
Other Study ID Numbers  ICMJE 14-001VI
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Roger K Cady, MD, Cady, Roger, M.D.
Study Sponsor  ICMJE Cady, Roger, M.D.
Collaborators  ICMJE Vivid Pharma Inc.
Investigators  ICMJE
Principal Investigator: Roger K Cady, MD Clinvest
PRS Account Cady, Roger, M.D.
Verification Date March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP